Surrozen has appointed Craig Parker to serve as CEO of the South San Francisco, CA, regenerative medicines developer. Parker takes the place of Tim Kutzkey, a managing partner at The Column Group, the venture capital firm that led Surrozen’s $33 million Series A financing last year. Kutzkey will now become chairman of Surrozen’s board of directors. Parker comes to Surrozen from Ireland-based Jazz Pharmaceuticals (NASDAQ: JAZZ), where he was senior vice president of corporate development. Surrozen is developing drugs targeting a molecular pathway that regulates tissue repair in the body.